It has been about a month since the last earnings report for United Therapeutics (UTHR) . Shares have added about 5.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is United Therapeutics due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for United Therapeutics Corporation before we dive into how investors and analysts have reacted as ...

Summary of United Therapeutics FY Conference Call Company Overview - **Company**: United Therapeutics (NasdaqGS: UTHR) - **Date of Conference**: March 02, 2026 - **Key Speakers**: Mike Bankowitz (President and COO), James Edgemon (CFO) Key Points Industry and Market Dynamics - **Pulmonary Arterial Hypertension (PAH)**: The company reported double-digit annual growth in its existing commercial business and expects this trend to continue over the next 18 months [2][3] - **Market Potential**: There are approximately 30,000 patients not currently on prostacyclin therapy, indicating a significant addressable market for ralinepag, which is expected to be a blockbuster drug with potential sales of around $2 billion by 2030 [9][10] Product Developments - **Ralinepag**: - Achieved a 55% reduction in the risk of clinical worsening in trials, with a notable delay in disease progression compared to placebo [4][5] - Expected to be the new standard of care for PAH, with a well-tolerated profile and potential for first-line use shortly after AMBITION therapy [7][8] - Pricing is anticipated to be comparable to existing prostacyclin therapies [13] - **Tyvaso**: - Positioned to launch as the best drug for Idiopathic Pulmonary Fibrosis (IPF) and is expected to benefit from a new soft mist inhaler that reduces cough, a common side effect of dry powder inhalers [20][23] - The IPF market in the U.S. is estimated to have over 100,000 patients, presenting a significant growth opportunity [37] Competitive Landscape - **Sotatercept and Liquidia**: The introduction of these products has not significantly impacted United Therapeutics' market share, with evidence suggesting a synergistic effect when used alongside prostacyclin therapies [16][17] - **Nebulizer vs. Soft Mist Inhaler**: The soft mist inhaler is expected to be preferred over nebulizers and dry powder inhalers due to its convenience and reduced dosing frequency [22][23] Regulatory and Approval Pathways - **FDA Interactions**: The company plans to file for FDA approval for ralinepag and the soft mist inhaler by mid-summer 2026, with ongoing discussions for potential accelerated approval pathways [36][40] Future Growth and Development - **Corporate Development**: United Therapeutics is focused on internal R&D and evaluating corporate development opportunities, particularly in pulmonary and cardiopulmonary areas [55][56] - **Xenotransplantation**: The company is advancing a xenokidney trial, targeting a large patient population with end-stage renal disease, with plans to open additional facilities for organ sourcing [62][71] Financial Outlook - **Cash Flow Management**: The company has successfully executed a $1 billion share repurchase and is focused on maintaining strong financial stewardship while exploring growth opportunities [56][57] Conclusion - United Therapeutics is well-positioned for significant growth in the PAH and IPF markets, with promising product developments and a strong pipeline. The company is actively managing its financial resources while exploring new opportunities in both existing and emerging therapeutic areas.

Core Insights - United Therapeutics (UTHR) reported Q4 2025 earnings per share (EPS) of $7.70, exceeding the Zacks Consensus Estimate of $6.78, with a year-over-year increase of 24% driven by higher product sales [1][7] - The company anticipates "double-digit revenue growth" in 2026 and aims for a $4 billion annualized revenue run rate in the second half of 2027 [2][3] Financial Performance - Q4 revenues were $790.2 million, missing the Zacks Consensus Estimate of $805 million, but reflecting a 7.3% year-over-year growth, primarily from Tyvaso and Orenitram [2] - For the full year 2025, total revenues reached $3.18 billion, an 11% increase from 2024, with net earnings of $27.86 per share compared to $24.64 in 2024 [11] Product Sales Breakdown - Combined sales of Tyvaso products were $464.3 million, up 12% year over year, although they fell short of the Zacks Consensus Estimate of $488 million [4] - Tyvaso DPI generated $338.6 million in revenue, a 24% increase year over year, aided by enhanced commercialization efforts [5] - Sales of nebulized Tyvaso were $125.7 million, down 12% due to lower volumes [8] - Orenitram sales rose 12% to $121.2 million, while Remodulin sales declined 5% to $128 million, and Unituxin sales decreased 8% to $62.3 million [8] Expenses - Research and development expenses were $139.5 million, up 4.3% year over year, reflecting increased clinical development costs [9] - Selling, general, and administrative expenses rose 13.1% to $190.6 million, driven by higher consulting and personnel costs [9] Pipeline Developments - Key phase III programs include Tyvaso for chronic fibrosing interstitial lung disease and oral ralinepag for PAH [12] - The TETON-2 study showed clinical benefits in idiopathic pulmonary fibrosis patients, with management believing it could expand Tyvaso's therapeutic reach [13] - The company is also conducting the TETON-1 study and plans to meet with the FDA to expedite regulatory review if results are favorable [14] - Top-line data from the ADVANCE OUTCOMES study for ralinepag is expected in the first half of 2026 [15]

Core Insights - United Therapeutics Corporation reported fourth-quarter results that exceeded earnings expectations but fell short on revenue, leading to a more than 9% increase in shares intra-day [1] Financial Performance - Adjusted earnings per share for the fourth quarter were $7.70, surpassing the consensus estimate of $7.10 by $0.60 [1] - Revenue for the fourth quarter totaled $790.2 million, below expectations of $815.24 million, but represented a 7% increase from $735.9 million in the prior-year quarter [2] - Full-year 2025 revenue reached a record $3.18 billion, up 11% from 2024 [2] Product Revenue Breakdown - Total Tyvaso revenue grew 12% to $464.3 million in the fourth quarter, driven by Tyvaso DPI, which increased 24% to $338.6 million [3] - Growth in Tyvaso revenue was attributed to higher quantities sold due to continued patient expansion and increased commercial utilization linked to Medicare Part D redesign under the Inflation Reduction Act [3] - Orenitram revenue rose 12% to $121.2 million [3] Net Income and Future Outlook - Net income for the quarter reached $364.3 million, or $7.70 per diluted share, compared to $301.3 million, or $6.19 per diluted share, in the fourth quarter of 2024 [4] - For full-year 2025, net income totaled $1.33 billion, up from $1.20 billion in 2024 [4] - Management indicated that the ADVANCE OUTCOMES and TETON-1 clinical programs are expected to deliver pivotal data that could expand treatment options [4]

Core Insights - United Therapeutics reported revenue of $790.2 million for the quarter ended December 2025, reflecting a 7.4% increase year-over-year, but fell short of the Zacks Consensus Estimate by 1.88% [1] - The company's EPS was $7.70, up from $6.19 in the same quarter last year, exceeding the consensus estimate of $6.78 by 13.5% [1] Revenue Breakdown - Revenues from the Rest-of-World segment were $37.4 million, surpassing the estimated $28.71 million, marking a 23.8% increase year-over-year [4] - U.S. revenues totaled $752.8 million, slightly below the estimated $753.92 million, with a year-over-year growth of 6.7% [4] - Remodulin in the U.S. generated $104.3 million, underperforming the estimate of $112 million, representing a year-over-year decline of 4.8% [4] - Tyvaso in the U.S. reported revenues of $457.2 million, slightly below the estimate of $464.91 million, with a year-over-year increase of 11.6% [4] - Adcirca revenues were $7.8 million, exceeding the estimate of $4.62 million, showing a significant year-over-year increase of 66% [4] - Orenitram generated $121.2 million, closely matching the estimate of $121.24 million, with a year-over-year growth of 12.4% [4] - Other products brought in $6.6 million, surpassing the average estimate of $5.1 million, reflecting a 20% year-over-year increase [4] - Unituxin revenues were $62.3 million, exceeding the estimate of $51.29 million, but showing a year-over-year decline of 7.7% [4] - Nebulized Tyvaso reported $125.7 million, below the estimate of $144.35 million, with a year-over-year decline of 11.9% [4] - Tyvaso DPI revenues were $338.6 million, exceeding the estimate of $313.3 million, marking a 23.9% increase year-over-year [4] Stock Performance - United Therapeutics shares have returned -0.7% over the past month, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - In 2025, the company achieved record-breaking revenue, surpassing $3 billion for the first time, with an 11% total revenue growth over 2024 [8] - For Q4 2025, total revenue was $790 million, representing a 7% increase from Q4 2024 [8] Business Line Data and Key Metrics Changes - Tyvaso revenue for Q4 was $464 million, a 12% increase year-over-year, driven by a 24% growth in Tyvaso DPI [9] - Orenitram and Remodulin continue to be foundational therapies in treating pulmonary hypertension, with ongoing studies reinforcing their benefits [12] Market Data and Key Metrics Changes - The referral rate for Tyvaso reached its highest level in two years, indicating strong underlying demand [10] - The company noted that sales trends can vary seasonally, with Q1 and Q4 typically being lighter ordering quarters [9] Company Strategy and Development Direction - The company is focused on launching three transformative products in 2027: a once-daily super prostacyclin for PAH, a cough-less inhaler for ILD, and a new treatment for IPF [7] - The company is also engaged in discussions with pharmaceutical companies regarding its AI-enabled digital lung model, which can predict trial outcomes more efficiently [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about upcoming clinical trial results and the potential for new product launches to drive future growth [6][7] - The company is committed to double-digit revenue growth and aims to reach a $4 billion revenue run rate by the end of 2027, independent of new product contributions [56] Other Important Information - The company is actively involved in transplantation research, with ongoing clinical trials for new organ products [35] - The Tresmi product, a soft mist inhaler, is expected to significantly improve patient adherence by reducing coughing, a common side effect of existing therapies [5][37] Q&A Session Summary Question: Confidence in Teton-1 data for IPF - Management expressed strong confidence in the Teton-1 study outcomes, citing similarities with Teton-2 results [18][19] Question: Impact from Uptravi on patient ads and competition - Management noted that Tyvaso remains the market leader, with strong referral rates and physician confidence despite initial curiosity about new entrants [46] Question: Details on soft mist inhaler studies - Management indicated that physicians will likely welcome the soft mist inhaler due to its ease of use and effectiveness, with further details to be disclosed post-FDA approval [50][51] Question: Contribution of new product launches to long-term growth - Management confirmed that the new product launches will enhance revenue growth beyond the projected $4 billion run rate, emphasizing their transformative nature [54][56] Question: Key outcomes to watch for Ralinepag - Management highlighted the importance of clinical worsening metrics and hospitalizations as key outcomes for Ralinepag, with anticipation for upcoming data [59][62]

Financial Data and Key Metrics Changes - In 2025, the company achieved record-breaking revenue, surpassing $3 billion for the first time, with an 11% total revenue growth compared to 2024 [8] - For Q4 2025, total revenue was $790 million, reflecting a 7% increase from Q4 2024 [8] - Tyvaso revenue for Q4 was $464 million, a 12% year-over-year increase, driven by a 24% growth in Tyvaso DPI [9] Business Line Data and Key Metrics Changes - Tyvaso's strong performance is attributed to its strategic positioning in the pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) markets, with expectations for continued double-digit growth [9][10] - Orenitram and Remodulin remain foundational therapies in treating pulmonary hypertension, with ongoing studies reinforcing their benefits [12] Market Data and Key Metrics Changes - The referral rate for Tyvaso reached its highest level in two years, indicating strong underlying demand [10] - The company noted that initial curiosity about new market entrants has not significantly impacted Tyvaso's market leadership, with referrals returning to pre-competitive launch levels [46] Company Strategy and Development Direction - The company is focused on innovative product development, with plans to launch three transformative products by 2027: a once-daily super prostacyclin for PAH, a cough-less inhaler for ILD, and a new treatment for IPF [7][56] - The company is also engaged in discussions with pharmaceutical companies regarding its AI-enabled digital lung model, which can predict trial outcomes more efficiently [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about upcoming clinical trial results, particularly for the TETON studies, and their potential to translate into successful outcomes [19][44] - The company is committed to maintaining double-digit revenue growth and anticipates reaching a $4 billion revenue run rate by the end of 2027, driven by existing products and new launches [56] Other Important Information - The company is actively involved in transplantation research, with ongoing clinical trials for innovative organ transplantation solutions [35] - The Tresmi product, a soft mist inhaler, is expected to significantly improve patient adherence by reducing coughing, a common side effect of existing therapies [5][37] Q&A Session Summary Question: Confidence in TETON-1 data and impact from Yutrepia - Management expressed strong confidence in the TETON-1 study outcomes based on positive results from TETON-2, with similar baseline characteristics [18][44] - The competitive impact from Yutrepia is being monitored, with Tyvaso maintaining its market leadership despite initial curiosity about new entrants [46] Question: Details on soft mist inhaler studies - Management indicated that physicians will likely respond positively to the soft mist inhaler due to its ease of use and effectiveness, with further details to be disclosed post-FDA approval [50][51] Question: Contribution of new product launches to long-term growth - The company reaffirmed its commitment to a $4 billion revenue run rate, with new product launches expected to enhance growth beyond this target [56] Question: Key outcomes to watch for Ralinepag - Management highlighted the importance of clinical worsening metrics, hospitalizations, and mortality rates as key outcomes for Ralinepag, with anticipation for upcoming trial results [60][62]

Financial Data and Key Metrics Changes - In 2025, the company achieved record-breaking revenue, with an 11% total revenue growth over 2024, surpassing $3 billion for the first time [7][8] - For Q4 2025, total revenue was $790 million, representing a 7% increase from Q4 2024 [7][8] Business Line Data and Key Metrics Changes - Tyvaso revenue for Q4 was $464 million, a 12% increase year-over-year, driven by a 24% growth in Tyvaso DPI [8][9] - Orenitram and Remodulin continue to be foundational therapies in treating pulmonary hypertension, with ongoing studies reinforcing their benefits [11] Market Data and Key Metrics Changes - The referral rate for Tyvaso reached its highest level in two years, indicating strong underlying demand [9] - The company noted that sales trends can vary seasonally, with Q1 and Q4 typically being lighter ordering quarters [8] Company Strategy and Development Direction - The company plans to launch three transformative products in 2027: a once-daily super prostacyclin for PAH, a cough-less inhaler for ILD, and a new treatment for IPF [6][35] - The company is focused on innovation, utilizing an AI-enabled digital lung model to enhance product development and reduce trial times [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about upcoming clinical trial results, particularly for the TETON-1 study, and expects to see similar positive outcomes as in TETON-2 [40][41] - The company anticipates continued double-digit revenue growth, supported by existing products and new launches [12][52] Other Important Information - The company is actively engaged in discussions with pharmaceutical companies regarding its AI-enabled digital lung model, which can predict trial outcomes more efficiently [30] - The company is also advancing its transplantation initiatives, with successful trials and plans for regulatory approval of new products [33][34] Q&A Session Summary Question: Confidence in TETON-1 data and impact from Uptravi - Management expressed strong confidence in TETON-1 outcomes based on TETON-2 results and noted that Tyvaso remains a market leader despite competition from Uptravi [16][43] Question: Details on the soft mist inhaler product - Management indicated that the soft mist inhaler is expected to be well-received by physicians and patients, with plans for FDA filing this year and launch next year [47] Question: Contribution of new product launches to long-term growth - Management confirmed a commitment to a $4 billion revenue run rate by 2027, with new product launches expected to enhance growth beyond this target [50][52] Question: Important outcomes for Ralinepag data - Management highlighted the importance of clinical worsening, hospitalizations, and mortality as key outcomes to watch for Ralinepag [55][58]

United Therapeutics Corporation Fourth Quarter 2025 Corporate Update February 25, 2026 2 INTRODUCTION Safe Harbor Statement Dr. Martine Rothblatt Michael Benkowitz All statements in this presentation are made as of February 25, 2026. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise. Statements included in this presentation that are not historical in nature are "forward-looking statements" within the meaning of the P ...

Core Viewpoint - Analysts forecast that United Therapeutics (UTHR) will report quarterly earnings of $6.78 per share, reflecting a year-over-year increase of 9.5%, with anticipated revenues of $805.31 million, marking a 9.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised downward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Estimates - Analysts estimate 'Revenues- Adcirca' will reach $4.62 million, a decrease of 1.6% from the year-ago quarter [5]. - The average prediction for 'Revenues- Orenitram' is $121.24 million, indicating a year-over-year increase of 12.5% [5]. - The consensus for 'Revenues- Other products' stands at $5.10 million, reflecting a year-over-year decline of 7.3% [5]. - 'Revenues- Remodulin' is expected to be $131.46 million, showing a decrease of 2.3% year over year [6]. - 'Revenues- Tyvaso' is projected to reach $488.25 million, indicating a year-over-year increase of 17.4% [6]. - 'Revenues- Unituxin' is expected to be $51.29 million, suggesting a significant decline of 24% year over year [6]. - 'Revenues- Nebulized Tyvaso' is forecasted at $144.35 million, reflecting a slight increase of 1.2% from the prior year [7]. - 'Revenues- Tyvaso DPI' is expected to reach $313.30 million, indicating a year-over-year increase of 14.7% [7]. - 'Revenues- United States' is projected to be $753.92 million, reflecting a change of 6.8% from the prior-year quarter [7]. - 'Revenues- Rest-of-World' is estimated at $28.71 million, suggesting a year-over-year decline of 4.9% [8]. Stock Performance - Over the past month, shares of United Therapeutics have returned +1.8%, contrasting with the Zacks S&P 500 composite's -0.8% change [8]. - Currently, UTHR holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].